Evolva Reaches Milestone in Roche Project

Evolva Holding SA (Reinach, Switzerland) confirmed with pharmaceutical company Roche that Evolva has achieved its first milestone in their collaboration together to create compounds with activity on targets in oncology and infectious disease. Roche and Evolva, which is also currently collaborating with IFF (New York) on a commercially viable biosynthetic route for the production of a key flavoring ingredient, began working on this project in January 2010, and Roche will now make a corresponding milestone payment to Evolva. The project milestone relates to the achievement of diverse, purified active compounds that derive from Evolva’s synthetic biology platform.